Dear reader of, please excuse the disruption. needs about $63500 in 2024. In 2023 we received donations of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 23,000 times a week, but only 75 people donate. If you find useful, please take a minute and support with your donation. Thank you!

Since 01.06.2021 is supported by the non-profit ADxS e.V..

$21963 of $63500 - as of 2024-05-31
Header Image
4. Dopamine formation and storage


4. Dopamine formation and storage

Dopamine is synthesized in several steps. First, L-phenylalanine from food is converted to L-tyrosine. L-tyrosine is then converted to L-dopa and finally to dopamine. Alternatively, dopamine can also be synthesized directly from L-phenylalanine. Another alternative synthesis pathway is via tyramine, which is converted to dopamine. Noradrenaline is synthesized by converting dopamine, while adrenaline is synthesized from noradrenaline.

Dopamine is formed in dopaminergic cells in various brain regions, primarily in the VTA (A10) and substantia nigra (A9) as well as in the retrorubral nucleus (A8) and the arcuate nucleus.
Dopamine from the VTA influences motivated behavior and reinforcement learning. A distinction is made between different types of VTA neurons, including purely dopaminergic, purely GABAergic and VGLUT2-positive neurons. These each have different functions and project to different regions of the brain.

The activity of dopamine synthesis is regulated by various enzymes and factors. These include tyrosine hydroxylase (TH), tetrahydrobiopterin (BH4), GTP cyclohydrolase 1 (GTPCH), aromatic L-amino acid decarboxylase (AADC), pyridoxal phosphate (vitamin B6) and oxygen concentration.
Mechanisms such as phosphorylation, dephosphorylation and feedback inhibition influence the activity of the enzymes. Binding to protein complexes and interaction with other proteins also play a role.

The synthesis and storage of dopamine in vesicles is carried out by the enzyme VMAT2.
Blockade of VMAT function leads to parkinsonian-like behavioral effects that can be remedied by L-DOPA. VMAT2 inhibitors inhibit dopamine formation and reduce dopamine release. The storage of dopamine in vesicles depends on the cytosolic dopamine concentration. VMAT2 can be regulated by several mechanisms, including cytosolic chloride concentration, acidification by V-ATPase, post-translational modifications and the amount of dopamine in the cytoplasm. Various drugs can increase or inhibit VMAT2 activity. Increased VMAT2 expression leads to an increase in the amount of dopamine in vesicles and dopamine release.

4. Synthesis and storage of dopamine, noradrenaline, adrenaline

4.1. Synthesis of dopamine, noradrenaline, adrenaline

The formation of dopamine takes place in several steps:12

  • L-phenylalanine from food
    is synthesized by phenylalanine hydroxylase using tetrahydrobiopterin (BH4), folic acid and oxygen
  • To L-Tyrosine
    this is achieved by tyrosine hydroxylase (TH) using BH4 and calcium citrate
  • To L-Dopa (dihydroxyphenylalanine)
    this is achieved by aromatic L-amino acid decarboxylase (AADC, dopa decarboxylase) with the consumption of pyridoxal phosphate (vitamin B6)
  • To dopamine and CO2 (carbon dioxide)

Alternative ways of synthesizing dopamine are 2

  • L-phenylalanine from food
    is synthesized by aromatic L-amino acid decarboxylase (AADC, dopa decarboxylase) using pyridoxal phosphate (vitamin B6)
  • To phenylethylalamine
    this becomes
  • To tyramine


  • L-tyrosine
    is synthesized by aromatic L-amino acid decarboxylase (AADC, dopa decarboxylase) using pyridoxal phosphate (vitamin B6)
  • To tyramine
    in humans, this is mediated by CYP2D63, in rats by CYP2D2, CYP2D4 and CYP2D184
  • To dopamine

This alternative synthesis pathway appears to be quantitatively modest under normal physiological conditions in rats, but may be more efficient in the human brain and may be particularly important when the main synthesis pathway is impaired (e.g. tyrosine hydroxylase deficiency or aromatic amino acid decarboxylase deficiency). Furthermore, alternative CYP2D6-mediated dopamine synthesis could be relatively important in individuals who have more than one CYP2D6 gene (e.g. in Mediterranean populations)5

There is an interesting in vivo study on the alternative synthesis pathway via tyramine in rats, in which the “classic” synthesis pathway via tyrosine was blocked.

The administration of a CYP2D inhibitor in rats with a blocked “classical” dopamine synthesis pathway caused the dopamine concentration to fall in several areas of the brain (particularly in the striatum and nucleus accumbens, to a lesser extent in the substantia nigra and frontal lobe). Tyramine administration into the striatum also led to a stronger increase in extracellular dopamine with unblocked CYP2D than with blocked CYP2D.6
This pathway appears to account for only a small proportion of total dopamine synthesis in rats.6 However, CYP2D enzymes are reported to be less efficient in rats than in humans, so the alternative pathway via tyramine and CYP2D may have a greater impact in humans than in rats.

The statistical over- and underrepresentation of slow and ultra-fast CYP2D6 metabolization types in various psychiatric disorders could at least be interpreted as an indication in this direction7, even if reliable studies are still lacking (early 2023).

This remains the case in dopaminergic cells.
In noradrenergic cells, dopamine is converted to noradrenaline:

  • Dopamine
    is produced by the enzyme dopamine β-hydroxylase (DHB) using oxidized vitamin C
  • To noradrenaline

This remains the case in noradrenergic cells.
Noradrenaline is converted to adrenaline in adrenergic cells:

  • Noradrenaline
    is synthesized by the enzyme phenylethanolamine N-methyltransferase (PNMTase) using S-adenosylmethionine (SAM), pyridoxal phosphate (vitamin B6) and vitamin B12
  • To adrenaline.

Dopamine is also a precursor (precursor) for

  • Isoquinoline alkaloids
    • E.g. Berber
  • Morphine

4.2. Individual elements of dopamine synthesis

4.2.1. L-phenylalanine

Phenylalanine inhibits the hydroxylation of tyrosine.8

While the administration of tyrosine increases dopa and dopamine in the retina of rats, the administration of phenylalanine does not lead directly to an increase in dopa in the retina, but only indirectly via the increase in tyrosine through phenylalanine hydroxylation in the liver.9
Phenylalanine inhibited the conversion of labeled tyrosine to DOPA less effectively than tyrosine inhibited the conversion of labeled phenylalanine to DOPA. This indicates that the tyrosine hydroxylase affinity of tyrosine is higher than that of phenylalanine.9
Studies in PC-12 cells indicate that almost all DOPA synthesized in the retina results from tyrosine at normal retinal tyrosine concentrations, regardless of retinal phenylalanine concentration. Fluctuations in retinal phenylalanine have little effect on total DOPA synthesis in the retina.9

Using PC-12 cells exposed to different concentrations of phenylalanine and tyrosine, it was shown that

  • High extracellular phenylalanine levels lead to a depletion of intracellular tyrosine and dopamine.
  • Unlike physiological phenylalanine concentrations (75 μM):10
    • low (35 μM) phenylalanine concentrations as well as
    • high tyrosine concentrations (275 or 835 μM)
      reduced levels of
      • cellular dopamine
      • Tyrosine hydroxylase (TH)
      • TH phosphorylation values

In the liver, phenylalanine is immediately metabolized to tyrosine.8

Phenylketonuria (PKU) is an inborn error of amino acid metabolism in which phenylalanine cannot be metabolized to tyrosine due to a lack of phenylalanine hydroxylases. PKU is associated with increased phenylalanine levels, reduced tyrosine levels and ADHD symptoms.

4.2.2. Tyrosine

Tyrosine is a precursor in the synthesis of dopamine. Although the rate-limiting enzyme of catecholamine synthesis is not tyrosine but tyrosine hydroxylase, an increase in tyrosine levels in the brain stimulates catecholamine production, but only in actively firing neurons 811

Tyrosine is oxidized by tyrosinase. Tyrosine increases dopamine and noradrenaline

Tyrosine administration increased extracellular dopamine in the striatum and nucleus accumbens in rats.12 Another source reported this for the striatum only if the animals had previously received a dopamine receptor antagonist (halperidol).13 Tyrosine administration also significantly increased (in light only) the conversion of tyrosine to L-dopa (part of the dopamine synthesis pathway) in the retina of rats14 and subsequently increased dopamine in the retina.15 Since dopamine suppresses melatonin, this pathway could influence the circadian rhythm. More on this at Melatonin and dopamine and the circadian rhythm in the article Melatonin in ADHD
In rats, the tyrosine level in the hypothalamus varies linearly with a range of protein content in the diet between 2 and 10 %. At 20 %, the tyrosine level in the hypothalamus hardly increased any further.8

Protein-rich food increases the tyrosine level in the brain. Theoretically, a protein-rich diet could therefore help to alleviate a dopamine deficiency and the resulting ADHD symptoms. However, the effect is likely to be small in people whose dopamine synthesis functions normally. If a dopamine deficiency is explicitly caused by dopamine synthesis problems due to tyrosine deficiency, the effect could be stronger. Although this is only very rarely the case, we believe it is conceivable that this could be one of the many pathways leading to ADHD.

This opens up the possibility of treatment with tyrosine for ADHD.
More on this under Tyrosine for ADHD. Tyrosine depletion reduces dopamine and noradrenaline

The amount of tyrosine available in the brain is also influenced by other large neutral amino acids that compete with tyrosine for the same transporter across the blood-brain barrier, e.g:816

  • Tryptophan
  • Phenylalanine
  • L-methionine
  • Histidine
  • Threonine
  • L-glycine
  • L-lysine
  • L-arginine
  • L-leucine
  • L-isoleucine
  • L-valine
  • but not alanine17

Therefore, administration of these large neutral amino acids (without tyrosine and without phenylalanine, as phenylalanine is immediately metabolized to tyrosine in the liver) can reduce brain tyrosine levels in the hypothalamus and retina within 2 hours.16 As a result, the dopamine level in the brain also decreases, but not in the PFC 818

Dopamine reduction in the brain through tyrosine depletion - indication of dopamine synthesis also in the target regions?

Studies on acute tyrosine/phenylalanine depletion in humans showed a dopamine deficiency in the target areas within a few hours. This is not consistent with the hypothesis that dopamine is synthesized in the nucleus alone and then transported by vesicles via the axons to the target areas, as this transport takes much longer than the onset of dopamine-deficiency-induced behavioral changes after tyrosine depletion.
This indicates that dopamine is also synthesized in dopaminergic target regions.
Perhaps these results would be much clearer if the duration of the tyrosine depletion were sufficiently long.

On the other hand, the substantia nigra, as part of the basal ganglia, is spatially close to the striatum. However, we have not yet been able to find any distance data.
However, with a transport speed of 25 to 40 cm / day, the observed behavioral changes due to tyrosine depletion within less than 2 hours should at best result in a distance of 2 to 3 cm. This seems unlikely to us.

This opens up treatment options for disorders characterized by excessive dopamine or noradrenaline levels.
More on this under Tyrosine for ADHD. Tyrosine excess causes inattention

Tyrosinemia (here: hereditary tyrosinemia type 1, HT-1 or TT-1), a rare (1:100,000 to 120,000 live births) disorder of tyrosine degradation, which leads to increased tyrosine levels, is associated with increased inattention.1920

4.2.3. Tyrosine hydroxylase (TH)

TH is the rate-limiting enzyme of dopamine synthesis. TH uses BH4 and molecular oxygen to convert tyrosine into DOPA.21

What influences the activity of TH thus influences dopamine synthesis. Some mechanisms alter the activity of TyrH, others simply bring the enzyme into the vicinity of other related proteins. Post-translational mechanisms of TH regulation include:21

  • Phosphorylation by kinases
    • The activity and stability of tyrosine hydroxylase is influenced by various kinases such as PKA, PKC, CaMPKII, PKG, MPK and ERK, which phosphorylate it at serine sites 8 (rat only), 19, 31 and 40. Phosphorylation of the tyrosine hydroxylase22
      • at Ser40 strongly increases TH activity (up to 10-fold)
      • to Ser31 slightly increases TH activity
      • at Ser19 or Ser8 (rat only) does not affect TH activity
      • at Ser19 increases the rate of Ser40 phosphorylation, which increases TH activity.
    • Furthermore, the arginine sites 37 and 38 appear to be able to regulate TH. Deletion or replacement of arginine 37 and 38 by glycine or glutamate resulted in improved BH4 affinity and thus increased TH activity.2
  • Dephosphorylation by phosphatases
    • The phosphatases PP2A and PP2C reverse the phosphorylation of TH and can thus deactivate TH2
  • Feedback inhibition
    • Catecholamines regulate TH. Catecholamines compete with BH4 for the binding of the iron(III) ion at the catalytic site of tyrosine hydroxylase. As a result, high catecholamine levels inhibit tyrosine hydroxylase and thus its own synthesis in the form of a feedback loop.2
    • Dopamine inhibits TH (also in the presence of GTPCH) as a negative feedback loop2
  • Oxidation by nitrites
    • TH can be inactivated by nitration using reactive nitrogen species (peroxynitrite) or by S-thiolation on cysteine residues.2
  • Integration into protein complexes
    • The stability, activity and probably also the intracellular localization of TH is also regulated by interactions with other proteins, such as2
      • 14-3-3
        • activated TH23
      • α-Synuclein
        • inhibits TH23
      • VMAT-2
      • AADC
      • GTPCH
      • DJ-1 (protein deglycase DJ-1, also known as Parkinson’s disease protein 7, PARK7) regulates TH.
        • DJ-1 regulates TH transcription by altering the acetylation status of the TH promoter. DJ-1 increases TH expression by inhibiting the sumoylation of PSF and preventing its sumoylation-dependent recruitment of histone deacetylase 1. Silencing of DJ-1 decreases the acetylation of TH promoter-bound histones. Histone deacetylase inhibitors restore DJ-1 siRNA-induced repression of TH. DJ-1 silencing thus results in reduced TH expression and reduced dopamine synthesis.24
        • The oxidation state of DJ-1 regulates its own activity and thus also TH expression21
          • DJ-1 is a transcriptional regulator
          • DJ-1 plays a role in bypassing oxidative stress
          • Certain DJ-1 variants have been identified in Parkinson’s disease25
          • DJ-1 is a TH repressor and binds to the promoter of the TyrH gene
          • DJ-1 binds directly to TyrH itself (as well as to AADC) binds and activates TH like AADC
  • Salsolinol, a tetrahydroisoquinoline alkaloid, inhibits TH26
    • is found at up to 25 µg/g in chocolate, cocoa and bananas, but cannot cross the blood-brain barrier.
    • is also formed endogenously in the organism
  • Cortisol inhibits TH.27
  • Alpha-methyl-p-tyrosine (AMPT, α-methyl-DL-tyrosine, αMPT) inhibits TH so strongly that catecholamine synthesis is blocked and the dopamine tissue level in DAT-KO mice drops to 0.2% of the normal level. This extreme dopamine deficiency after AMPT causes Parkinson’s symptoms such as severe akinesia, rigidity, tremor and ptosis.28
  • Aspirin in low doses (2 mg / kg / day) increased TH and subsequently dopamine in the striatum in mice.29
  • Prolactin is said to increase TH synthesis and TH activity and thus dopamine synthesis within 12 to 16 hours3031

Tyrosine hydroxylase prefers to bind to tyrosine rather than phenylalanine.9

4.2.4. Tetrahydrobiopterin (BH4, sapropterin, INN)

Tetrahydrobiopterin (BH4) is produced from guanosine triphosphate by GTP cyclohydrolase 1 (GTPCH). GTPCH is the limiting factor in BH4 synthesis.32

  • excessive BH4 levels block GTPCH
    • this prevents GTPCH-TH interaction
    • therefore too much BH4 impairs the TH
  • bH4 levels that are too low inhibit TH
    • BH4 is a cofactor for TH
  • BH4 only promotes tyrosine hydroxylase from 10 to 25 and up to 100 microM. Lower or higher quantities inhibit it2
    BH4 deficiency or BH4 excess can therefore hinder dopamine synthesis. BH4 administration can improve ADHD symptoms resulting from phenylketunorie.33

Genetic BH4 disorders such as

  • autosomal recessive (AR) guanosine triphosphate cyclohydrolase deficiency (GTPCH deficiency)
  • 6-Pyruvoyl tetrahydropterin synthase deficiency (PTPS)

seem to contribute to ADHD and other mental disorders such as anxiety, depression, aggression or oppositional defiant behavior.34

4.2.5. GTP cyclohydrolase 1 (GTPCH)

GTPCH interacts with tyrosine hydroxylase2

  • cAMP administration increases GTPCH gene expression
  • Phenylalanine induces GTPCH activity
  • Phosphorylation of Ser81 increases GTPCH activity.
  • BH4 inhibits GTPCH via the GTPCH feedback regulatory protein (GFRP) in the form of a feedback loop

GTPCH interacts with tyrosine hydroxylase2

  • The interaction depends on the phosphorylation of TH and GTPCH.
  • Interaction with TH prevented BH4-mediated inhibition of GTPCH
    • this increased the GTPCH and TH activity
  • GTPCH activity is stimulated by phosphorylated TH
  • Dopamine synthesis is dependent on GTPCH
  • BH4 does not increase TH activity in Drosophila with inactive GTPCH gene versions
  • TH activity depends on an interaction between TH and GTPCH

4.2.6. Aromatic L-amino acid decarboxylase (AADC, Dopa decarboxylase)

AADC is involved in the synthesis of catecholamines, indoleamines and trace amines.35

  • Decarboxylation of aromatic amino acids occurs in different cell types, so that trace amines can theoretically be formed in these:36
    • Nerve cells
    • Glial cells
    • Blood vessels
    • Cells of the gastrointestinal tract
    • Kidney
    • Liver
    • Lung
    • Stomach
      • Serotonergic AADC, especially in the pylorus37

Cells containing AADC were found in the following areas of the brain:38

  • Raphe nuclei (serotonergic, very strong AADC)
  • Pons ventral (serotonergic, very strong AADC)
  • Medulla ventral (serotonergic, very strong AADC)
  • Mesencephalic reticular formation (dopaminergic, moderate to strong AADC)
  • Substantia nigra (dopaminergic, moderate to strong AADC)
  • VTA (domapinergic, moderate to strong AADC)
  • Locus coeruleus (noradrenergic, moderate to strong AADC)
  • Subcoeruleus nuclei (noradrenergic, moderate to strong AADC)
  • Median and ventrolateral parts of the intermediate reticular nucleus in the medulla oblongata (noradrenergic / adrenergic, moderate AADC)
  • Forebrain: few non-aminergic AADC-positive neurons (D-neurons); these were not detectable in other parts of the human brain.

AADC catalyzes the decarboxylation of various aromatic l-amino acids such as:

  • L-DOPA
  • L-tyrosine
  • L-tryptophan
  • L-histidine

AADC is itself subject to regulatory influences:

  • Transcriptional (slower, longer-lasting regulation through adaptation of gene expression)2
    • Expression is influenced by
      • Different use of promoters
      • Different splicing
  • Post-translational (fast-acting, short-term mechanism)
    • Phosphorylation35
      • By PKA in the striatum and midbrain
      • AADC increased by 20 to 70
    • PH value changes39
    • Denaturation39
    • Neurotransmitter2
      • Antagonists enhance, agonists reduce AADC activity40
      • Dopamine via
        • Dopamine D1 to D4 receptors40
        • Dopamine antagonists increase AADC, e.g.
          • Cis-flupenthixol
          • Haloperidol
        • Dopamine increase reduces AADC2
          • MOA inhibitors
        • The destruction of dopaminergic cells only reduced the dopaminergic 3,4-dihydroxyphenylalanine decarboxylase, not the serotonergic 5-hydroxytryptophan decarboxylase activity, which actually increased41
        • In contrast, another study found that the destruction of both dopaminergic and serotonergic neurons reduced both dopaminergic and serotonergic AADC equally.42
      • Serotonin via
        • 5-HT 1A receptor40
        • 5-HT 2A receptor40
      • Glutamate via
        • NMDA receptor40
      • Nicotinic acetylcholine receptors40

Different forms of AADC cause the dopaminergic and serotonergic decarboxylase. The two forms showed different activity maxima depending on pH, temperature and substrate concentrations:43

  • Dopaminerg: 3,4-dihydroxyphenylalanine decarboxylase
    * The dopaminergic AADC activity:
    * Only in soluble cell fractions43
    * Distribution corresponded to lactic acid dehydrogenase43
    * Pyridoxal-5-phosphate increases this by a factor of 2044
    * Carboxyl scavengers inhibit them completely43
  • Serotonerg: 5-hydroxytryptophan decarboxylase
    * In soluble and particulate cell fractions43
    * Pyridoxal-5-phosphate doubles this43
    * Pyridoxal-P antagonists hardly affect them43
    * Serotonergic AADC is potentiated by 3-isobutyl-1-methylxanthine.37

In ADHD, AADC activity was found to be reduced by 50% in the medial and left PFC, but not in the striatum or midbrain.45 Another study by the same research group with a smaller number of subjects found increased AADC activity in ADHD46

AADC is also relevant in the synthesis of melatonin. There could be a connection here with the increased sleep problems in ADHD.

4.2.7. Pyridoxal phosphate (PLP, PALP, P5P, active vitamin B6)

Pyridoxal phosphate (PLP, PALP, P5P) is one of the most important cofactors in the animal organism. Pyridoxal phosphate is the metabolically active form of vitamin B6.
PLP is involved in various amino acid reactions:

  • Transamination
    catalyzed e.g. by
    • GABA transaminase
  • Decarboxylation
    catalyzed e.g. by
    • AADC
    • Histidine decarboxylase
    • Ornithine decarboxylase
  • Dehydration
  • Breakdown of glycogen

4.2.8. Oxygen concentration and dopamine synthesis

The intracellular O2 concentration in brain tissue influences the synthesis and stability of dopamine. The O2 concentration in brain tissue is normally 1-5 %, which is significantly lower than the 20 % in the atmosphere. Increased oxygen levels induce dopamine oxidation and thus the formation of ROS.47 Hypoxia increases TH activity and thus dopamine synthesis.48

Erythropoietine, a cytokine that is primarily released from the kidneys when blood oxygen saturation is reduced,49 showed a protective effect against the death of dopaminergic cells in hypoxia and ischemia in animal experiments.5051
In ADHD sufferers, a correlation was found between elevated erythropoietin levels in the blood and inattention and strongly elevated erythropoietin levels and hyperactivity.52

Hypoxia causes global neurodegeneration in the hippocampus. This is accompanied (in rats) by an increase in HDAC2. Subsequently, hypoxic rats show a decrease in H3K9ac and H3K14ac, accompanied by a significant decrease in SNAP-25 levels. Administration of the broad-spectrum HDAC inhibitor of sodium butyrate (NaB), abolishes hypoacetylation and increases SNAP-25 levels.53

4.2.9. Sport and thinking influence dopamine synthesis

Dopamine production is increased by

  • Exercise and sport54
  • (Strategic) thinking (context: workaholism)

Some people with ADHD play sports excessively. Sport is “needed”. Sport increases stress resistance.

4.3. Site of dopamine synthesis

4.3.1. Dopamine synthesis within the neurons

Neurotransmitters are formed in the cell body (soma) and, enclosed in vesicles, are transported to the synapses mainly through the microtubules via the axons in the nerve fibers at up to approx. 25 to 40 cm/day.555657

4.3.2. Brain regions in which dopamine is produced

The formation of dopamine in the brain takes place in nerve cells from:5859 A8 to A15, as well as in the small cell groups of the Aaq (rostral in the central gray, midbrain) and the telencephalic group (A16, A17).60

  • in the ventral midbrain (around 70 % of DA neurons)
    • VTA (in A10)
      • Mesolimbic system; target: limbic system
      • Mesocortical system; target: cortex
    • Substantia nigra (in A9)
      • Pars reticulata (SNpr) and Pars compacta (SNpc)
      • Mesostriatal system (nigrostriatal system); target: basal ganglia (including striatum)
    • Nucleus retrorubralis (nucleus retrorubricus, A8, in the thalamus).
      • Mesostriatal system (nigrostriatal system); target: basal ganglia (including striatum)
  • in the diencephalon: A11 to A15
    • subparafascicular thalamic nucleus, A11
      • from here, dopamine innervates the superior olivary complex and the inferior colliculus in the brainstem (A13)
      • where it is supposed to regulate auditory processing
    • Nucleus arcuatus (nucleus infundibularis, core area at the lower end of the infundibulum of the hypothalamus, A12)
      • Tuberoinfundibular system; target: anterior pituitary gland
      • Inhibition of prolactin
    • Dopaminergic neurons of the preoptic area (A14)
      • release DA into the pituitary portal vein system and thereby regulate the secretion of prolactin and growth hormone61
    • The A15 neurons are located in the periventricular area of the rostral hypothalamus61
  • in the telencephalon (end brain)
    • glomerular layer of the olfactory bulb (A16)
    • Retina (A17)
      • Dopamine is formed in amacrine and interplexiform cells in the retina62
      • Lack of bright daylight in childhood promotes myopia due to dopamine deficiency in the eye
  • in the brain stem
    • Locus coeruleus63646566
    • dopaminergic projection in dorsal hippocampus (73 % of dopaminergic tone in dorsal hippocampus; remainder from VTA)
    • dopaminergic projection in PFC

After synthesis in the nerve cell, the dopamine is packaged in vesicles and transported through the axons to the nerve endings. This axonal transport of vesicles occurs at a rate of 25 to 40 cm/day.
Dopamine is synthesized in the cytosol. The cytosol is located in the soma, but also in the axon, so that in dopaminergic cells dopamine is also synthesized in the axon and its endings (terminals).57 Substantia nigra pars compacta

The substantia nigra pars compacta contains more than 70 % of all dopaminergic neurons in humans (in young people there are around 400,000 to 600,000 in total). It is located in Brodman area A9 in the ventral midbrain and bears its name (“black substance”) due to the high iron and neuromelanin levels, which make it appear darker than neighboring areas.60

A dense network of axons emanates from the dopaminergic neurons of the substantia nigra, via which the target regions in the dorsal striatum in particular are supplied with dopamine.67 VTA: dopamine, GABA, VGLUT2

Dopamine from the VTA modulates motivated behavior and reinforcement learning.
The other neurotransmitters released by VTA neurons also influence motivation.

There are 6 types of VTA neurons:

  • purely dopaminergic68
    • Activation through positive stimuli such as food, sugar, water or addictive substances
    • Projection according to: Nucleus accumbens
      • NAc D1 type MSN
        • activated when dopamine is released, by strengthening the PKA pathway
        • encode reward/positive stimuli
        • directly inhibit the ventral mesencephalon, which in turn inhibits the thalamus (direct pathway).
      • NAc D2 type MSN
        • activated when dopamine is low by activation of the adenosine A2A receptor (A2AR), which increases intracellular calcium levels
        • encode aversive/negative stimuli
        • disinhibit the ventral mesencephalon by suppressing the ventral pallidum (indirect pathway)
    • half of the dopaminergic VTA neurons are active and fire spontaneously
      • the other half is inactive and does not fire spontaneously69 because they are constantly hyperpolarized by an inhibitory GABAergic influence from the ventral pallidum and thus kept inactive. By suppressing the pallidal afferents, the neurons are freed from the GABAergic inhibition and fire spontaneously again.7071
  • purely GABAerg68
    • GABAergic VTA neurons project to the nucleus accumbens, PFC, central amygdala, lateral habenula and dorsal raphe nuclei.
    • GABA-A receptors cause hyperpolarization of postneurons through the influx of chloride ions
    • GABA-B receptors further induce hyperpolarization by suppressing adenylyl cyclase and voltage-gated calcium channels
    • Tasks:
      • Inhibition of dopaminergic neurons in the VTA and inhibition of distal brain regions
      • Aversion and interruption of rewards
      • Response to cues and reward-associated learning
      • VTA GABAergic neurons become active and suppress VTA DA neurons when mice anticipate a reward such as sucrose or cocaine after being exposed to a stimulus not associated with the reward. GABAergic neurons in the VTA thus control the dopaminergic activity of the VTA by interrupting reward consumption and disrupting responsiveness
      • regulate place preference when the projection of caudal GABAergic neurons of the VTA to serotonergic neurons of the DRN is activated
      • GABAergic VTA neurons predict the absence of a reward72
  • purely VGLUT2 (type 2 vesicular glutamate transporter)68
    • Knockout of glutamatergic VTA neurons reduces motivated behavior
    • VGLUT2-VTA neurons become active during drug self-administration, drug-seeking behavior and reinforcement
    • project into the medial shell of the nucleus accumbens, ventral palladium and lateral habenula
    • directly excite the nucleus accumbens and ventral palladium
    • inhibit lateral habenula
    • Glutamate in the axon terminal binds to N-methyl-D-aspartate receptors (NMDA-Rs), leading to calcium influx that activates the pERK signaling pathway
    • become active in classical conditioning when exposed to a reward or electric shock
      • active firing in response to the conditioned stimulus associated with the reward
    • glutamatergic VTA neurons predict a reward72
  • VGLUT2/dopamine neurons68
    • release glutamate and dopamine together at the axon terminals
      • Glutamate via asymmetric synapses
      • Dopamine via symmetrical synapses
    • VGLUT2-DA neurons increase survivability and axonal arborization of VTA dopamine neurons
    • project to the cholinergic neurons in the medial shell of the nucleus accumbens
    • contribute to switching the behavioral response in tasks with cognitive reinforcement
  • VGLUT2/GABA neurons68
    • differ from pure VGLUT neurons at the circuit level
    • are strongly associated with lateral habenula and ventral palladium
    • become active in classical conditioning when exposed to a reward or electric shock
      • no active firing in response to the conditioned stimulus associated with the reward
    • VGLUT2-GABA neurons
      • encode the valence itself
      • signal rewarding and aversive outcomes without signaling learned cues related to these outcomes72
  • GABA dopamine neurons68
    • are strongly oriented towards the nucleus accumbens
    • Release of neurotransmitters is controlled by uptake mechanism, not by the classic GAD1/2 pathway
      • VTA-DA neurons synthesize GABA via aldehyde dehydrogenase 1A1
      • GABA vesicles are filled by vesicular monoamine transporters, not by vesicular GABA transporters

Overall, VTA neurons are68

  • dopaminergic: > 70 %
  • GABAerg: approx. 30 %
  • VGLUT2erg: approx. 30 %

The release of dopamine from the VTA follows a 12-hour rhythm. VTA neurons fire highest early in the light cycle and early in the dark cycle. In particular, a small subgroup of VTA neurons appears to be active at night.73
Neurons of the substantia nigra, on the other hand, showed no changes across the circadian time.

4.4. Storage of dopamine in the vesicles (VMAT)

Dopamine and other catecholamines are stored in vesicles after their formation by VMAT2, where they are stored until they are released:74

  • small synaptic vesicles in neurons
  • small and large dense nuclear vesicles in neurons and neuroendocrine cells.

With a slightly acidic pH value, the vesicles protect the dopamine from oxidation in the cytosol.275

VMAT2-KO mice have reduced dopamine levels in the neurons. Dopamine cannot be released by electrical signals in these mice, but can be released by amphetamine.76 Missing or excessively inhibited VMAT2 causes excessive cellular dopamine levels, which have a neurotoxic effect after oxidation. VMAT-Full-KO mice usually only survive for a few days.

While it was previously assumed that vesicles harbor uniformly large quantities (a “quantum”) of neurotransmitters, a number of factors are now known to influence the amount of neurotransmitters in vesicles and the amount released from vesicles.77

4.4.1. VMAT isoforms

2 VMAT isoforms78

Both belong to the SLC18 family.

  • VMAT1
    • Is only expressed in endocrine and paracrine cells associated with the stomach, intestine and sympathetic nervous system
  • VMAT2
    • Is expressed by monoaminergic neurons throughout the CNS (rat), particularly in79
      • Midbrain
      • Striatum
      • Olfactory tubercle
      • The dopaminergic paraventricular nuclei
      • Nucleus tuberomammillaris
      • Nucleus raphe
      • Locus coeruleus.
    • In dopamine neurons on both types of secretory vesicles
      • Small synaptic vesicles
      • Large dense core vesicles

There are other vesicular transporters for other neurotransmitters:77

  • Vesicular acetylcholine transporter (VAChT)
  • Three vesicular glutamate transporters (VGLUT1, VGLUT2, VGLUT3)
  • Vesicular GABA/glycine transporter (VGAT; other name: vesicular inhibitory amino acid transporter, VIAAT)
  • Vesicular nucleotide transporter (VNUT).

4.4.2. Regulation of VMAT

Inhibition of the general VMAT function with reserpine led to clear parkinsonian-like behavioral effects in rats. These could be remedied by the dopamine prodrug L-DOPA78
Since L-dopa is only helpful in ADHD in rare cases, VMAT could be involved in ADHD correspondingly rarely.
The selective VMAT2 antagonist tetrabenazine also inhibits dopamine formation.

VMAT2 inhibitors inhibit methamphetamine and amphetamine self-administration in rats78

  • (+)eCYY477, VMAT2 inhibitor (a dihydrotetrabenazine derivative)
  • Lobelan
  • GZ-793A (Lobalan analog)
    • also reduces the release of dopamine, especially in limbic end fields (e.g. nucleus accumbens shell).

VMAT2 are dependent on V-ATPase (vacuolar-type H+ ATPase) for their dopaminergic function. Disruptions in the function of V-ATPase or the proton gradient created by it impair the storage of dopamine in the vesicles by VMAT2.

The storage of dopamine in vesicles via VMAT2 also depends on the amount of cytosolic dopamine concentration. L-dopa increases dopamine within the cell. Increased L-DOPA causes an increase in vesicle size without a change in vesicle number. The increased vesicle size represents a larger releasable dopamine pool78

VMAT2 can be regulated by78

  • the cytosolic chloride concentration
    • up to a certain maximum, a higher cytosolic chloride concentration promotes dopamine storage by VMAT2
  • acidification by V-ATPase is a critical mediator for the increase in dopamine levels by VMAT2
  • post-translational modifications
  • Amount of dopamine in the cytoplasm appears to directly influence VMAT2
  • Changes in the expression level due to
    • Transcription factors
    • Protein kinases
      • Protein Kinase A (PKA)
        • influences VMAT2 expression indirectly:
          • regulates N-terminal glycosylation
          • directly phosphorylates cAMP response element-binding protein (CREB) for trafficking and transcription activation
    • heterotrimeric G proteins
      • depending on an intralumenal loop
    • Bonding partner interactions
    • Early childhood (stress) experiences80
    • Activity
      • VMAT2 expression can be up- or downregulated depending on activity
    • medicinal
      • Dopamine reuptake inhibitors increase VMAT2
        • Methylphenidate
        • Cocaine
      • Drugs that promote dopamine release reduce VMAT2
        • Amphetamine
          • causes emptying of the vesicular dopamine pool into the cytoplasm
          • causes deacidification of the secretory vesicles
          • typical for DAT-reversing drugs
          • different from DAT inhibitors such as methylphenidate
        • Methamphetamine
      • Apomorphine
        • D2 agonist
          • D2 agonists increase VMAT2 activity, D2 antagonists appear to inhibit VMAT2
        • D1 partial agonist
      • Reserpine
        • inhibits VMAT2

4.4.3. Effect of VMAT2

Increased VMAT2 expression increases78

  • Amount of dopamine in vesicles
  • Amount of dopamine released from vesicles
  • Frequency of release events from vesicles

VMAT2 forms complexes with TH and AADC enzymes and thus also directly influences dopamine synthesis.
Dopamine is synthesized in several steps. First, L-phenylalanine from food is converted to L-tyrosine. L-tyrosine is then converted to L-dopa and finally to dopamine. Alternatively, dopamine can also be synthesized directly from L-phenylalanine. Another alternative synthesis pathway is via tyramine, which is converted to dopamine. Noradrenaline is synthesized by converting dopamine, while adrenaline is synthesized from noradrenaline.

The formation of dopamine takes place in various regions of the brain, including the VTA, the substantia nigra, the retrorubral nucleus and the arcuate nucleus. Dopamine from the VTA influences motivated behavior and reinforcement learning. Different types of VTA neurons are distinguished, including purely dopaminergic, purely GABAergic and VGLUT2-positive neurons. These each have different functions and project to different regions of the brain.

The activity of dopamine synthesis is regulated by various enzymes and factors. These include tyrosine hydroxylase (TH), tetrahydrobiopterin (BH4), GTP cyclohydrolase 1 (GTPCH), aromatic L-amino acid decarboxylase (AADC), pyridoxal phosphate (vitamin B6) and oxygen concentration. Different mechanisms, such as phosphorylation, dephosphorylation and feedback inhibition, influence the activity of the enzymes. Binding to protein complexes and interaction with other proteins also play a role.

The synthesis and storage of dopamine in vesicles is carried out by the enzyme VMAT2. There are two isoforms of VMAT, VMAT1 and VMAT2, whereby VMAT2 is mainly expressed in the monoaminergic neurons of the central nervous system.

In summary, the synthesis and storage of dopamine, noradrenaline and adrenaline is regulated by various enzymes, factors and brain regions. The activity of these processes is important for the function of the dopaminergic system and has an impact on behavior, motivation and mental disorders such as ADHD.

The regulation of VMAT2 function can be influenced by various factors. Blocking VMAT function leads to parkinsonian-like behavioral effects, which can be remedied by L-DOPA. VMAT2 inhibitors inhibit dopamine formation and reduce dopamine release. The storage of dopamine in vesicles depends on the cytosolic dopamine concentration. VMAT2 can be regulated by several mechanisms, including cytosolic chloride concentration, acidification by V-ATPase, post-translational modifications and the amount of dopamine in the cytoplasm. Various drugs can increase or inhibit VMAT2 activity. Increased VMAT2 expression leads to an increase in the amount of dopamine in vesicles and dopamine release.

  1. Wolf, Calabrese (2020): Stressmedizin & Stresspsychologie; Seite 302

  2. Meiser, Weindl, Hiller (2013): Complexity of dopamine metabolism. Cell Commun Signal. 2013 May 17;11(1):34. doi: 10.1186/1478-811X-11-34. PMID: 23683503; PMCID: PMC3693914. REVIEW

  3. Niwa T, Shizuku M, Yamano K (2017): Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6. Arch Biochem Biophys. 2017 Apr 15;620:23-27. doi: 10.1016/ PMID: 28347660.

  4. Anna Haduch A, Bromek E, Daniel WA (2013): Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacol Rep. 2013;65(6):1519-28. doi: 10.1016/s1734-1140(13)71513-5. PMID: 24553000.

  5. Haduch A, Bromek E, Daniel WA (2013): Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacol Rep. 2013;65(6):1519-28. doi: 10.1016/s1734-1140(13)71513-5. PMID: 24553000.

  6. Bromek, Haduch, Gołembiowska, Daniel (2011): Cytochrome P450 mediates dopamine formation in the brain in vivo. J Neurochem. 2011 Sep;118(5):806-15. doi: 10.1111/j.1471-4159.2011.07339.x. PMID: 21651557.

  7. Peñas-Lledó EM, Llerena A. CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol. 2014 Apr;77(4):673-83. doi: 10.1111/bcp.12227. PMID: 24033670; PMCID: PMC3971983.

  8. Fernstrom JD, Fernstrom MH (2007): Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr. 2007 Jun;137(6 Suppl 1):1539S-1547S; discussion 1548S. doi: 10.1093/jn/137.6.1539S. PMID: 17513421., REVIEW

  9. Fernstrom MH, Baker RL, Fernstrom JD (1989): In vivo tyrosine hydroxylation rate in retina: effects of phenylalanine and tyrosine administration in rats pretreated with p-chlorophenylalanine. Brain Res. 1989 Oct 16;499(2):291-8. doi: 10.1016/0006-8993(89)90777-4. PMID: 2572300.

  10. Szigetvari PD, Patil S, Birkeland E, Kleppe R, Haavik J (2023): The effects of phenylalanine and tyrosine levels on dopamine production in rat PC12 cells. Implications for treatment of phenylketonuria, tyrosinemia type 1 and comorbid neurodevelopmental disorders. Neurochem Int. 2023 Oct 19:105629. doi: 10.1016/j.neuint.2023.105629. PMID: 37865339.

  11. Wurtman RJ, Larin F, Mostafapour S, Fernstrom JD (1974): Brain catechol synthesis: control by train tyrosine concentration. Science. 1974 Jul 12;185(4146):183-4. doi: 10.1126/science.185.4146.183. PMID: 4276197.

  12. During MJ, Acworth IN, Wurtman RJ (1988): Effects of systemic L-tyrosine on dopamine release from rat corpus striatum and nucleus accumbens. Brain Res. 1988 Jun 14;452(1-2):378-80. doi: 10.1016/0006-8993(88)90043-1. PMID: 3401745.

  13. Scally MC, Ulus I, Wurtman RJ (1977): Brain tyrosine level controls striatal dopamine synthesis in haloperidol-treated rats. J Neural Transm. 1977;41(1):1-6. doi: 10.1007/BF01252960. PMID: 21228.

  14. Fernstrom MH, Volk EA, Fernstrom JD, Iuvone PM (1986): Effect of tyrosine administration on dopa accumulation in light- and dark-adapted retinas from normal and diabetic rats. Life Sci. 1986 Dec 1;39(22):2049-57. doi: 10.1016/0024-3205(86)90355-3. PMID: 2878335.

  15. Gibson CJ (1986): Dietary control of retinal dopamine synthesis. Brain Res. 1986 Sep 10;382(1):195-8. doi: 10.1016/0006-8993(86)90132-0. PMID: 3768676.

  16. Fernstrom MH, Fernstrom JD (1995): Acute tyrosine depletion reduces tyrosine hydroxylation rate in rat central nervous system. Life Sci. 1995;57(9):PL97-102. doi: 10.1016/0024-3205(95)02026-f. PMID: 7630309.

  17. Sved AF, Fernstrom JD, Wurtman RJ (1979): Tyrosine administration reduces blood pressure and enhances brain norepinephrine release in spontaneously hypertensive rats. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3511-4. doi: 10.1073/pnas.76.7.3511. PMID: 291018; PMCID: PMC383857.

  18. Biggio G, Porceddu ML, Gessa GL (1976): Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3’,5’-monophosphate content in the rat caudate nucleus induced by the acute administration of an aminoacid mixture lacking tyrosine and phenylalanine. J Neurochem. 1976 Jun;26(6):1253-5. doi: 10.1111/j.1471-4159.1976.tb07014.x. PMID: 180254.

  19. Barone H, Bliksrud YT, Elgen IB, Szigetvari PD, Kleppe R, Ghorbani S, Hansen EV, Haavik J (2020): Tyrosinemia Type 1 and symptoms of ADHD: Biochemical mechanisms and implications for treatment and prognosis. Am J Med Genet B Neuropsychiatr Genet. 2020 Mar;183(2):95-105. doi: 10.1002/ajmg.b.32764. PMID: 31633311.

  20. Pohorecka M, Biernacka M, Jakubowska-Winecka A, Biernacki M, Kuśmierska K, Kowalik A, Sykut-Cegielska J (2012): Behavioral and intellectual functioning in patients with tyrosinemia type I. Pediatr Endocrinol Diabetes Metab. 2012;18(3):96-100. PMID: 23146787.

  21. Daubner, Le, Wang (2011): Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 2011 Apr 1;508(1):1-12. doi: 10.1016/ PMID: 21176768; PMCID: PMC3065393. REVIEW

  22. Dunkley, Bobrovskaya, Graham, von Nagy-Felsobuki, Dickson (2004): Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem. 2004 Dec;91(5):1025-43. doi: 10.1111/j.1471-4159.2004.02797.x. PMID: 15569247. REVIEW

  23. Perez, Waymire, Lin, Liu, Guo, Zigmond (2002): A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci. 2002 Apr 15;22(8):3090-9. doi: 10.1523/JNEUROSCI.22-08-03090.2002. Erratum in: J Neurosci 2002 Oct 15;22(20):9142. PMID: 11943812; PMCID: PMC6757524.

  24. Zhong, Kim, Rizzu, Geula, Porter, Pothos, Squitieri, Heutink, Xu (2006): DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J Biol Chem. 2006 Jul 28;281(30):20940-20948. doi: 10.1074/jbc.M601935200. PMID: 16731528.

  25. Yang, Wood, Latchman (2009): Molecular basis of Parkinson’s disease. Neuroreport. 2009 Jan 28;20(2):150-6. doi: 10.1097/WNR.0b013e32831c50df. PMID: 19151598. REVIEW

  26. Napolitano, Manini, d’Ischia (2011): Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr Med Chem. 2011;18(12):1832-45. doi: 10.2174/092986711795496863. PMID: 21466469.

  27. Bieger (2011): Neurostressguide, Seite 11

  28. Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, Gainetdinov RR (2005): Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol. 2005 Aug;3(8):e271. doi: 10.1371/journal.pbio.0030271. PMID: 16050778; PMCID: PMC1181539.

  29. Rangasamy, Dasarathi, Pahan, Jana, Pahan (2019): Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson’s Disease. J Neuroimmune Pharmacol. 2019 Jun;14(2):173-187. doi: 10.1007/s11481-018-9808-3. PMID: 30187283; PMCID: PMC6401361.

  30. Moore KE, Demarest KT, Johnston CA. Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed Proc. 1980 Sep;39(11):2912-6. PMID: 7409209.

  31. Cincotta AH (2023): Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects. Int J Mol Sci. 2023 Aug 26;24(17):13255. doi: 10.3390/ijms241713255. PMID: 37686060; PMCID: PMC10487918.

  32. Werner, Blau, Thöny (2011):Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J. 2011 Sep 15;438(3):397-414. doi: 10.1042/BJ20110293. PMID: 21867484. REVIEW

  33. Burton, Grant, Feigenbaum, Singh, Hendren, Siriwardena, Phillips, Sanchez-Valle, Waisbren, Gillis, Prasad, Merilainen, Lang, Zhang, Yu, Stahl (2015): A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria. Mol Genet Metab. 2015 Mar;114(3):415-24. doi: 10.1016/j.ymgme.2014.11.011. PMID: 25533024.

  34. Parfyonov, Friedlander, Banno, Elbe, Horvath (2022): Psychiatric Manifestations in Patients with Biopterin Defects. Neuropediatrics. 2022 Jan 28. doi: 10.1055/s-0042-1742323. PMID: 35098520.

  35. Duchemin, Berry, Neff, Hadjiconstantinou (2000): Phosphorylation and activation of brain aromatic L-amino acid decarboxylase by cyclic AMP-dependent protein kinase. J Neurochem. 2000 Aug;75(2):725-31. doi: 10.1046/j.1471-4159.2000.0750725.x. PMID: 10899948.

  36. Gainetdinov, Hoener, Berry (2018): Trace Amines and Their Receptors. Pharmacol Rev. 2018 Jul;70(3):549-620. doi: 10.1124/pr.117.015305. PMID: 29941461. REVIEW

  37. Ohta, Takebe, Murakami, Takahama, Morimura (2017): Tyramine and β-phenylethylamine, from fermented food products, as agonists for the human trace amine-associated receptor 1 (hTAAR1) in the stomach. Biosci Biotechnol Biochem. 2017 May;81(5):1002-1006. doi: 10.1080/09168451.2016.1274640. PMID: 28084165.

  38. Kitahama K, Ikemoto K, Jouvet A, Araneda S, Nagatsu I, Raynaud B, Nishimura A, Nishi K, Niwa S. Aromatic L-amino acid decarboxylase-immunoreactive structures in human midbrain, pons, and medulla. J Chem Neuroanat. 2009 Oct;38(2):130-40. doi: 10.1016/j.jchemneu.2009.06.010. PMID: 19589383.

  39. Bender, Coulson (1972): Variations in aromatic amino acid decarboxylase activity towards DOPA and 5-hydroxytryptophan caused by pH changes and denaturation. J Neurochem. 1972 Dec;19(12):2801-10. doi: 10.1111/j.1471-4159.1972.tb03817.x. PMID: 4652630.

  40. Hadjiconstantinou, Neff (2008): Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson’s disease. CNS Neurosci Ther. 2008 Winter;14(4):340-51. doi: 10.1111/j.1755-5949.2008.00058.x. PMID: 19040557; PMCID: PMC6494005. REVIEW

  41. Sims, Bloom (1973): Rat brain L-3,4-dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities: differential effect of 6-hydroxydopamine. Brain Res. 1973 Jan 15;49(1):165-75. doi: 10.1016/0006-8993(73)90408-3. PMID: 4540548.

  42. Dairman, Horst, Marchelle, Bautz (1975): The proportionate loss of L-3,4-dihydroxyphenylalanine and L-5-hydroxttryptophan decarboxylating activity in rat central nervous system following intracisternal administration of 5, 6-dihydroxytryptamine or 6-hydroxydopamine. J Neurochem. 1975 Apr;24(4):619-23. PMID: 1079044.

  43. Sims, Davis, Bloom (1973): Activities of 3,4-dihydroxy-L-phenylalanine and 5-hydroxy-L-tryptophan decarboxylases in rat brain: assay characteristics and distribution. J Neurochem. 1973 Feb;20(2):449-64. doi: 10.1111/j.1471-4159.1973.tb12144.x. PMID: 4540567.

  44. ähnlich: Siow, Dakshinamurti (1985): Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in adult rat brain. Exp Brain Res. 1985;59(3):575-81. doi: 10.1007/BF00261349. PMID: 3875501.

  45. Ernst, Zametkin, Matochik, Jons, Cohen (1998): DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci. 1998 Aug 1;18(15):5901-7. doi: 10.1523/JNEUROSCI.18-15-05901.1998. PMID: 9671677; PMCID: PMC6793062. n = 40

  46. Ernst, Zametkin, Matochik, Pascualvaca, Jons, Cohen (1999): High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry. 1999 Aug;156(8):1209-15. doi: 10.1176/ajp.156.8.1209. PMID: 10450262. n = 20

  47. Studer, Csete, Lee, Kabbani, Walikonis, Wold, McKay (2000): Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci. 2000 Oct 1;20(19):7377-83. doi: 10.1523/JNEUROSCI.20-19-07377.2000. PMID: 11007896; PMCID: PMC6772777.

  48. Kumar, Kim, Lee, Ramachandran, Prabhakar (2003): Activation of tyrosine hydroxylase by intermittent hypoxia: involvement of serine phosphorylation. J Appl Physiol (1985). 2003 Aug;95(2):536-44. doi: 10.1152/japplphysiol.00186.2003. PMID: 12692140.

  49. Flexikon: Erythropoietin

  50. McPherson, Demers, Juul (2007): Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology. 2007;91(1):36-43. doi: 10.1159/000096969. PMID: 17344650.

  51. Demers, McPherson, Juul (2005): Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res. 2005 Aug;58(2):297-301. doi: 10.1203/01.PDR.0000169971.64558.5A. PMID: 16055937.

  52. Shim, Kim, Hwangbo, Yoon, Kim, Lee, Woo, Bahk (2021): The Relationship between Plasma Erythropoietin Levels and Symptoms of Attention Deficit Hyperactivity Disorder. Clin Psychopharmacol Neurosci. 2021 May 31;19(2):334-340. doi: 10.9758/cpn.2021.19.2.334. PMID: 33888662.

  53. Xylaki M, Atzler B, Outeiro TF (2019): Epigenetics of the Synapse in Neurodegeneration. Curr Neurol Neurosci Rep. 2019 Aug 23;19(10):72. doi: 10.1007/s11910-019-0995-y. PMID: 31440934; PMCID: PMC6706357. REVIEW

  54. Simchen, Helga:; dort: was bewirken die Botenstoffe?

  55. Munk (2008): Taschenlehrbuch Biologie: Biochemie – Zellbiologie. Seite 453

  56. Stevens, Polleux, Barres (2021): The Cells of the Nevrous System. In: Kandel, Koester, Mack, Siegelbaum (2021): Principles of Neuronal Science

  57. Mussel M, Zeevy K, Diamant H, Nevo U (2014): Drag of the cytosol as a transport mechanism in neurons. Biophys J. 2014 Jun 17;106(12):2710-9. doi: 10.1016/j.bpj.2014.04.037. PMID: 24940788; PMCID: PMC4070075.

  58. Kizer JS, Palkovits M, Brownstein MJ (1976): The projections of the A8, A9 and A10 dopaminergic cell bodies: evidence for a nigral-hypothalamic-median eminence dopaminergic pathway. Brain Res. 1976 May 28;108(2):363-70. doi: 10.1016/0006-8993(76)90192-x. PMID: 1276901.

  59. Speranza L, di Porzio U, Viggiano D, de Donato A, Volpicelli F (2021): Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control. Cells. 2021 Mar 26;10(4):735. doi: 10.3390/cells10040735. PMID: 33810328; PMCID: PMC8066851. REVIEW

  60. Rillich (2019): Das dopaminerge System im Gehirn des Menschen: molekulare Grundlagen, Anatomie, Physiologie und Pathologie

  61. Henrich (2019): The Locus coeruleus in Parkinson’s disease

  62. Frederick JM, Rayborn ME, Laties AM, Lam DM, Hollyfield JG (1982): Dopaminergic neurons in the human retina. J Comp Neurol. 1982 Sep 1;210(1):65-79. doi: 10.1002/cne.902100108. PMID: 6127354.

  63. Kempadoo KA, Mosharov EV, Choi SJ, Sulzer D, Kandel ER (2016): Dopamine release from the locus coeruleus to the dorsal hippocampus promotes spatial learning and memory. Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14835-14840. doi: 10.1073/pnas.1616515114. PMID: 27930324; PMCID: PMC5187750.

  64. Lemon N, Manahan-Vaughan D (2012): Dopamine D1/D5 receptors contribute to de novo hippocampal LTD mediated by novel spatial exploration or locus coeruleus activity. Cereb Cortex. 2012 Sep;22(9):2131-8. doi: 10.1093/cercor/bhr297. PMID: 22038910; PMCID: PMC3412443.

  65. Devoto P, Flore G (2006): On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons? Curr Neuropharmacol. 2006 Apr;4(2):115-25. doi: 10.2174/157015906776359559. PMID: 18615131; PMCID: PMC2430672.

  66. McNamara CG, Dupret D (2017): Two sources of dopamine for the hippocampus. Trends Neurosci. 2017 Jul;40(7):383-384. doi: 10.1016/j.tins.2017.05.005. PMID: 28511793; PMCID: PMC5489110.

  67. Zhang, Doyon, Clark, Phillips, Dani (2009): Controls of tonic and phasic dopamine transmission in the dorsal and ventral striatum. Mol Pharmacol. 2009 Aug;76(2):396-404. doi: 10.1124/mol.109.056317. PMID: 19460877; PMCID: PMC2713129.

  68. Kim MJ, Kaang BK (2022): Distinct cell populations of ventral tegmental area process motivated behavior. Korean J Physiol Pharmacol. 2022 Sep 1;26(5):307-312. doi: 10.4196/kjpp.2022.26.5.307. PMID: 36039731.

  69. Grace AA, Bunney BS (1984): The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci. 1984 Nov;4(11):2866-76. doi: 10.1523/JNEUROSCI.04-11-02866.1984. PMID: 6150070; PMCID: PMC6564731.

  70. Floresco SB, West AR, Ash B, Moore H, Grace AA (2003): Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci. 2003 Sep;6(9):968-73. doi: 10.1038/nn1103. PMID: 12897785.

  71. Véronneau-Veilleux F, Robaey P, Ursino M, Nekka F (2022): A mechanistic model of ADHD as resulting from dopamine phasic/tonic imbalance during reinforcement learning. Front Comput Neurosci. 2022 Jul 18;16:849323. doi: 10.3389/fncom.2022.849323. PMID: 35923915; PMCID: PMC9342605.

  72. Root, Barker, Estrin, Miranda-Barrientos, Liu B, Zhang S, Wang HL, Vautier, Ramakrishnan, Kim YS, Fenno, Deisseroth, Morales (2020): Distinct Signaling by Ventral Tegmental Area Glutamate, GABA, and Combinatorial Glutamate-GABA Neurons in Motivated Behavior. Cell Rep. 2020 Sep 1;32(9):108094. doi: 10.1016/j.celrep.2020.108094. PMID: 32877676; PMCID: PMC7556367.

  73. Tang Q, Assali DR, Güler AD, Steele AD (2022): Dopamine systems and biological rhythms: Let’s get a move on. Front Integr Neurosci. 2022 Jul 27;16:957193. doi: 10.3389/fnint.2022.957193. PMID: 35965599; PMCID: PMC9364481. REVIEW

  74. Pereira, Sulzer (2012): Mechanisms of dopamine quantal size regulation. Front Biosci (Landmark Ed). 2012 Jun 1;17(7):2740-67. doi: 10.2741/4083. PMID: 22652810. REVIEW

  75. Vergo S, Johansen JL, Leist M, Lotharius J (2007): Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 2007 Dec 14;1185:18-32. doi: 10.1016/j.brainres.2007.09.028. PMID: 18028884.

  76. Fon, Pothos, Sun, Killeen, Sulzer, Edwards (1997): Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron. 1997 Dec;19(6):1271-83. doi: 10.1016/s0896-6273(00)80418-3. PMID: 9427250.

  77. Takamori (2016): Presynaptic Molecular Determinants of Quantal Size. Front Synaptic Neurosci. 2016 Feb 8;8:2. doi: 10.3389/fnsyn.2016.00002. PMID: 26903855; PMCID: PMC4744840. REVIEW

  78. Mulvihill (2019): Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters. Neurochem Int. 2019 Jan;122:94-105. doi: 10.1016/j.neuint.2018.11.004. PMID: 30465801. REVIEW

  79. Cliburn RA, Dunn AR, Stout KA, Hoffman CA, Lohr KM, Bernstein AI, Winokur EJ, Burkett J, Schmitz Y, Caudle WM, Miller GW (2017): Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. J Chem Neuroanat. 2017 Oct;83-84:82-90. doi: 10.1016/j.jchemneu.2016.11.003. PMID: 27836486; PMCID: PMC5878016.

  80. Barr, Moriceau, Shionoya, Muzny, Gao, Wang, Sullivan (2009): Transitions in infant learning are modulated by dopamine in the amygdala. Nat Neurosci. 2009 Nov;12(11):1367-9. doi: 10.1038/nn.2403. Epub 2009 Sep 27. PMID: 19783994; PMCID: PMC2783302.